Carfilzomib

Likelihood of LVDD is Predictive of Carfilzomib-Induced Cardiovascular AEs in R/R Multiple Myeloma

July 12, 2019

In this retrospective study, researchers investigated whether assessing left ventricular diastolic function in patients receiving carfilzomib for relapsed or refractory multiple myeloma improved risk of cardiovascular adverse events.

Multiple Myeloma

Carfilzomib Benefits May Outweigh Cardiovascular Risk in Multiple Myeloma

James Nam, PharmD

July 18, 2018

In an analysis of 11 studies, researchers investigated whether the benefits of carfilzomib for multiple myeloma outweigh the cardiovascular risks. However, the researchers recommend careful monitoring and management of blood pressure and volume status as good clinical practice, regardless.

Next post in Multiple Myeloma

Carfilzomib

Likelihood of LVDD is Predictive of Carfilzomib-Induced Cardiovascular AEs in R/R Multiple Myeloma

Carfilzomib Benefits May Outweigh Cardiovascular Risk in Multiple Myeloma

Qualitative Analysis of Myeloma Patients’ Experience Following Hematopoietic Stem Cell Transplant